Shanghai - Delayed Quote CNY
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS)
As of 11:29 AM GMT+8. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
840,443.29
816,765.08
764,547.39
569,698.34
409,249.35
Cost of Revenue
368,218.28
367,151.36
370,794.88
257,575.33
178,295.42
Gross Profit
472,225.01
449,613.73
393,752.51
312,123.01
230,953.93
Operating Expense
164,717.74
187,551.83
179,663.54
152,629.57
110,321.45
Operating Income
307,507.27
262,061.90
214,088.97
159,493.44
120,632.48
Net Non Operating Interest Income Expense
24,504.80
22,289.68
1,671.54
3,905.25
6,050.01
Pretax Income
314,676.88
290,762.31
255,859.02
159,391.23
95,497.97
Tax Provision
41,139.27
36,860.34
20,483.19
13,461.04
8,661.94
Net Income Common Stockholders
273,537.61
253,901.97
235,375.83
145,930.19
86,836.03
Basic EPS
0.39
0.31
0.29
0.18
0.12
Diluted EPS
0.39
0.31
0.29
0.18
0.12
Basic Average Shares
645,169.01
826,657.57
803,722.34
794,508.79
744,618.97
Diluted Average Shares
645,169.01
826,657.57
803,722.34
794,508.79
744,618.97
Total Operating Income as Reported
315,283.53
290,823.30
257,714.65
160,151.99
96,613.81
Total Expenses
532,936.01
554,703.18
550,458.42
410,204.90
288,616.87
Net Income from Continuing & Discontinued Operation
273,537.61
253,901.97
235,375.83
145,930.19
86,836.03
Normalized Income
288,542.17
262,975.12
236,232.04
141,975.05
90,693.34
Interest Income
32,367.45
30,561.96
8,223.07
5,784.32
7,654.70
Interest Expense
7,569.40
7,994.94
6,106.64
1,466.47
1,384.07
Net Interest Income
24,504.80
22,289.68
1,671.54
3,905.25
6,050.01
EBIT
322,246.28
298,757.25
261,965.66
160,857.69
96,882.04
EBITDA
345,023.13
339,350.42
296,443.37
190,881.45
122,307.62
Reconciled Cost of Revenue
368,218.28
367,151.36
370,794.88
257,575.33
178,295.42
Reconciled Depreciation
22,776.84
40,593.17
34,477.71
30,023.76
25,425.58
Net Income from Continuing Operation Net Minority Interest
273,537.61
253,901.97
235,375.83
145,930.19
86,836.03
Total Unusual Items Excluding Goodwill
-17,261.20
-10,390.35
-930.72
4,319.97
-4,242.08
Total Unusual Items
-17,261.20
-10,390.35
-930.72
4,319.97
-4,242.08
Normalized EBITDA
362,284.33
349,740.77
297,374.09
186,561.48
126,549.70
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-2,256.64
-1,317.20
-74.51
364.83
-384.77
12/31/2020 - 5/9/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2142.HK HBM Holdings Limited
1.200
-2.44%
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
193.600
-1.58%
2315.HK Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
6.730
-4.94%
2616.HK CStone Pharmaceuticals
1.760
-1.12%
9688.HK Zai Lab Limited
22.550
-1.31%
1877.HK Shanghai Junshi Biosciences Co., Ltd.
14.340
-1.10%
1801.HK Innovent Biologics, Inc.
43.950
-2.33%